SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on May 28, 2019. The filing reports a corporate governance event regarding the transfer of the company's stock listing. Note: The request metadata referenced "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
This filing is a current report regarding a listing transfer and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- Listing Transfer: The Board of Directors approved the voluntary transfer of the Company's Common Stock from NYSE American to the Nasdaq Capital Market.
- Trading Timeline: Trading on NYSE American ceased at market close on June 7, 2019. Trading on Nasdaq commenced on June 10, 2019.
- New Ticker Symbol: The stock began trading under the symbol REXN.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a press release (Exhibit 99.1) regarding the listing transfer. No financial guidance, management commentary on operational outlook, specific risk factors, or contingencies are detailed within the text of this 8-K.
Investor Verification Checklist
- Verify the new ticker symbol REXN on the Nasdaq Capital Market.
- Confirm the trading suspension date on NYSE American (June 7, 2019) and resumption date on Nasdaq (June 10, 2019).
- Review the attached press release (Exhibit 99.1) for any additional context on the strategic rationale for the listing transfer.
- Consult the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.